Form 4: Viking Therapeutics Director Exercises Options and Sells Shares Under 10b5-1 Plan

J Matthew Singleton, a director at Viking Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 20, 2024, J Matthew Singleton, a director of Viking Therapeutics, Inc., executed transactions involving the company's common stock.
• Singleton exercised stock options to acquire 10,300 shares at a price of $1.19 per share.
• Simultaneously, Singleton sold 10,300 shares at $69.50 per share.
• Following these transactions, Singleton directly owns 9,500 shares of Viking Therapeutics.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 16, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports routine transactions under a pre-arranged trading plan. There is no indication of positive or negative implications for the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. These filings provide transparency into insider transactions and are closely watched by investors.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a director.
• The impact is likely minimal as the transactions were conducted under a pre-arranged trading plan.

Key Dates